Document is current
Any future updates will be listed below
-
Authors
Kawamura, Tomoyuki https://orcid.org/0000-0002-3593-9910
Lee, Takumi
Shintani-Tachi, Mami
Terada, Izuru
Wakasugi, Naoko https://orcid.org/0000-0002-9671-7174
-
Funding
Funding for this research was provided by:
Astellas Pharma
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 15 October 2025
First Online: 18 November 2025
Declarations
:
: Tomoyuki Kawamura has received payment or honoraria from Eli Lilly Japan K.K., Medtronic Japan Co., Ltd., Novo Nordisk Pharma Ltd., and Terumo Corporation. Takumi Lee, Mami Shintani-Tachi, Izuru Terada, and Naoko Wakasugi are employees of Astellas Pharma Inc.
: This study was conducted in accordance with Good Post-marketing Study Practice (GPSP), an ordinance issued by Japan’s Ministry of Health, Labour and Welfare, establishing the standards for implementation of post-marketing surveillance for approved drugs in Japan. The study protocol was reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and the study outline was publicly disclosed in advance by the PMDA. Informed consent was not required because all data were anonymized and collected retrospectively. Permission to access the JMDC Claims Database was acquired from JMDC Inc.
